Daiwa analyst Narumi Nakagiri downgraded Bristol Myers (BMY) to Neutral from Outperform with a $42 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers says FDA accepts sBLA for Breyanzi
- Bristol-Myers Squibb’s New Study on Schizophrenia Treatment Satisfaction
- Bristol-Myers Squibb’s New Phase 3 Trial: A Potential Game-Changer in Lung Cancer Treatment?
- Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Drug Pipeline and Strategic Reviews
- Bristol Myers price target lowered to $58 from $62 at Bernstein